(Press-News.org) Patients with stage III melanoma were treated with nivolumab (anti-PD1) and relatlimab (anti-LAG-3) before surgery
87% of patients remained alive and 80% were disease free four years after treatment
Nearly all patients whose tumors responded to treatment before surgery remained disease-free after four years
Researchers found potential biomarkers that can highly predict which patients have better outcomes or are at high risk of recurrence
HOUSTON, JULY 10, 2025 ― Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87% of patients with stage III melanoma remained alive, according to new results from a study led by researchers at The University of Texas MD Anderson Cancer Center.
Long-term follow-up data from this Phase II study, published today in the Journal of Clinical Oncology, demonstrate this combination provides long-term benefits to patients when given before and after surgery, and identified unique biomarkers associated with better outcomes and lower chance of recurrence.
Of the 30 patients enrolled on the study, 80% had no recurrence of their cancer after four years. For patients who had a significant response, called a major pathologic response, from treatment when evaluated at the time of surgery, even more remained recurrence free, at 95%.
“If immunotherapy eliminates most of the tumor before surgery, then we have sufficiently trained the immune system for an antitumor response, which minimizes the possibility of recurrence,” said corresponding author Elizabeth Burton, Ph.D., executive director of MD Anderson’s Strategic Research Initiative Development (STRIDE) program. “We are encouraged by these results showing the long-term benefit of this combination and approach for our patients and the opportunity it provides to learn as much as possible about what is driving this response to treatment.”
Stage III melanoma has a high risk of recurrence following surgery, highlighting an opportunity for the addition of pre-surgical, or neoadjuvant, immunotherapy to shrink the tumor and prime the immune system to guard against future recurrences.
Relatlimab is a LAG-3 inhibitor, an immune checkpoint inhibitor that was approved in 2022 in combination with nivolumab by the Food and Drug Administration (FDA) for patients with advanced melanoma based on the Phase II/III RELATIVITY-047 clinical trial, led by Hussein Tawbi, M.D., Ph.D., professor of Melanoma Medical Oncology.
In this Phase II trial, led by Rodabe Amaria, M.D., professor of Melanoma Medical Oncology, researchers were first to evaluate this combination in the neoadjuvant setting for earlier stage disease. Initial findings reported this combination was safe and effective in that setting.
Because of the strong association to outcomes with major pathologic response, researchers evaluated biomarkers to better understand the factors associated with treatment response.
They found that patients who had high pre-treatment levels of one biomarker, called TIGIT, or low levels of another biomarker, called B7-H3, had the best chance of remaining recurrence-free, highlighting the potential to use these markers to predict patient responses in the future.
“This study highlights the tremendous impact integrating excellent multi-disciplinary care with team science can have on improving patient outcomes while advancing science and innovation. The neoadjuvant treatment approach allows us to quickly evaluate the clinical impact of a treatment and serves as a springboard for biomarker research.” Burton said. “This is a good starting point for where researchers can look in terms of mechanisms of resistance that could be potential therapeutic targets in the future.”
Going forward, the authors are collaborating with researchers at MD Anderson’s James P. Allison Institute to validate these biomarkers and to use spatial profiling to further understand where they are located and how they can impact the tumor microenvironment.
This clinical trial was funded by Bristol Myers Squibb, with additional support for this study by MD Anderson’s Moon Shots Program, the National Cancer Institute (P50CA221703, P30 CA016672, UM1 TR004538, and P30 CA008748). Tawbi and Amaria were co-senior authors on this study, together with Jennifer Wargo, M.D., professor of Surgical Oncology. A full list of collaborating authors and their disclosures can be found here.
- 30 -
END
Researchers present BioEmu – a new AI model that rapidly and accurately predicts the full range of shapes a protein can adopt, offering a faster, cheaper alternative to traditional molecular simulations. Proteins and their complexes are essential to nearly every biological process and are central to advances in medicine and biotechnology. While recent breakthroughs in sequencing and deep learning have made it easier to determine a protein’s sequence and structure, understanding how proteins function by shifting between different shapes in response to other molecules remains a central challenge. ...
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) is a progressive neurological disease with an average age of onset of 43 years and an average life expectancy of only 3 to 5 years after symptoms begin. ALSP is caused by microglial mutation, the immune cells of the central nervous system (CNS). Currently, ALSP has no cure and treatments are limited.
All microglia rely on a kinase called colony-stimulating factor 1 receptor (CSF1R), which is only found in microglia and other myeloid cells. When CSF1R gene carries pathogenic ...
-With images-
In the tropical rainforests of Fiji, a genus of unusual plants has developed a remarkably simple but highly effective way to prevent violence between rival ant colonies: architecture.
In a new study published in Science, an international team led by Professor Guillaume Chomicki at Durham University has revealed how some species of the epiphytic plant Squamellaria (part of the coffee family, Rubiaceae) form peaceful and productive partnerships with multiple aggressive ant species simply by physically ...
Odd plants from a remote Pacific island reveal new insights into an important ecological question: how unrelated and antagonistic partners can form long-term mutualistic relationships with the same host.
Scientists studying ant plants in Fiji have discovered one way that a host plant can keep the peace among residents that might otherwise kill each other. By providing separate chambers inside a gradually enlarging tuber -- each chamber with an entry hole from the outside but no connection to any adjacent chamber -- the Squamellaria plant prevents conflicts between the multiple ant species that ...
A new study suggests that, under realistic scenarios of high emissions and socioeconomic development, annual heat-related deaths in the U.K. could rise to about 50 times current rates by the 2070s, but that climate change mitigation and adaptation could significantly limit this rise. Rebecca Cole of the London School of Hygiene and Tropical Medicine, U.K., and colleagues present these findings in the open-access journal PLOS Climate.
Heatwaves are expected to become more frequent and more intense in coming decades in the U.K. ...
UCL Press Release
Under embargo until Thursday 10 July 2025, 19:00 UK time, 14:00 US Eastern time
Annual heat-related deaths projected to increase significantly due to climate and population change
The annual number of heat-related deaths in England and Wales is set to rise up to fiftyfold over the next 50 years because of climate change, finds new research by UCL and the London School of Hygiene & Tropical Medicine.
Their paper, published in PLoS Climate, analysed the impacts of 15 ...
An international team led by researchers at The Hospital for Sick Children (SickKids), Princess Margaret Cancer Centre, Dalhousie University, the University of Exeter (UK) and the Medical University of Vienna (Austria) has uncovered a surprising way compartments within cells work together to defend themselves against oxidative stress, a finding that could shift how we understand age-associated conditions such as diabetes and neurodegenerative diseases.
Published today in Science, the study reveals a newly identified mechanism between two key compartments of the cell (mitochondria ...
(Santa Barbara, Calif.) — Rivers are Earth’s arteries. Water, sediment and nutrients self-organize into diverse, dynamic channels as they journey from the mountains to the sea. Some rivers carve out a single pathway, while others divide into multiple interwoven threads. These channel patterns shape flood risks, erosion hazards and ecosystem services for more than 3 billion people who live along river corridors worldwide.
Understanding why some waterways form single channels, while others divide into many threads, has perplexed researchers for over a century. ...
AURORA, Colo. (July 10, 2025) – A new study from the University of Colorado Anschutz Medical Campus has upended decades of neuroscience dogma, revealing that dopamine, a neurotransmitter critical for movement, motivation, learning and mood, communicates in the brain with extraordinary precision, not broad diffusion as previously believed. This groundbreaking research offers fresh hope for millions of people living with dopamine-related disorders, marking a significant advance in the quest for precision-based neuroscience and medicine.
For years, scientists thought of ...
Can artificial intelligence, or AI, potentially transform health care for the better?
Now, rising to the challenge, an Arizona State University team of researchers has built a powerful new AI tool, called Ark+, to help doctors read chest X‑rays better and improve health care outcomes.
“Ark+ is designed to be an open, reliable and ultimately useful tool in real-world health care systems,” said Jianming “Jimmy” Liang, an ASU professor from the College of Health Solutions, and lead author of the study recently published in the prestigious journal Nature.
In a proof-of-concept study, the new AI tool demonstrated ...
